Literature DB >> 22555345

The relationship between tumor inflammatory cell infiltrate and outcome in patients with pancreatic ductal adenocarcinoma.

Nigel B Jamieson1, Mohamed Mohamed, Karin A Oien, Alan K Foulis, Euan J Dickson, Clem W Imrie, C Ross Carter, Colin J McKay, Donald C McMillan.   

Abstract

BACKGROUND: The tumor-associated inflammatory cell infiltrate is recognized to have prognostic value in various common solid tumors. However, the prognostic value of the tumor inflammatory cell infiltrate has not been established in pancreatic ductal adenocarcinoma (PDAC) nor has its relationship with the systemic inflammatory response.
METHODS: Retrospective study was made of 173 patients who underwent surgery between 1997 and 2009. Routine pathology specimens were scored according to density of the tumor inflammatory cell infiltrate, and biochemical data were collected preoperatively.
RESULTS: Low-grade tumor inflammatory cell infiltrate was associated with earlier tumor recurrence (P < 0.001) and particularly in the liver (P = 0.027). It was also associated with T3 tumors (P < 0.05), lymph node involvement (P < 0.05), and resection margin involvement (P < 0.05). On univariate survival analysis, age <65 years (P < 0.05), mGPS (P < 0.001), increased tumor stage (P < 0.01), nodal involvement (P < 0.01), size (P < 0.05), grade (P < 0.05), perineural invasion (P < 0.05), venous invasion (P < 0.01), resection margin involvement (P ≤ 0.001), vascular reconstruction (P < 0.05), and no adjuvant chemotherapy (P < 0.05) were associated with poor survival. In contrast, high-grade tumor inflammatory cell infiltrate was associated with better survival (P < 0.001). On multivariate survival analysis, mGPS [hazard ratio (HR): 1.77, 95% confidence interval (95% CI): 1.19-2.62, P = 0.005], tumor stage (HR: 2.21, 95% CI: 1.16-4.23, P = 0.016), resection margin involvement (HR: 2.19, 95% CI: 1.41-3.44, P = 0.001), venous invasion (HR: 1.79, 95% CI: 1.22-2.63, P = 0.003), tumor inflammatory cell infiltrate (HR: 0.37, 95% CI: 0.25-0.55, P = 0.0001), and adjuvant chemotherapy (P = 0.04) were independently prognostic.
CONCLUSIONS: The results of the study show, for the first time, that the presence of a high-grade tumor inflammatory cell infiltrate is an independent predictor of prolonged overall survival following resection for PDAC. Furthermore, measures of the local and the systemic inflammatory response were inversely associated.

Entities:  

Mesh:

Year:  2012        PMID: 22555345     DOI: 10.1245/s10434-012-2370-y

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  29 in total

1.  The predictive value and role of stromal tumor-infiltrating lymphocytes in pancreatic ductal adenocarcinoma (PDAC).

Authors:  Tao Lianyuan; Xiu Dianrong; Yuan Chunhui; Ma Zhaolai; Jiang Bin
Journal:  Cancer Biol Ther       Date:  2018-02-22       Impact factor: 4.742

2.  Activation of the IL-6R/Jak/stat pathway is associated with a poor outcome in resected pancreatic ductal adenocarcinoma.

Authors:  Simon M Denley; Nigel B Jamieson; Pamela McCall; Karin A Oien; Jennifer P Morton; C Ross Carter; Joanne Edwards; Colin J McKay
Journal:  J Gastrointest Surg       Date:  2013-02-23       Impact factor: 3.452

3.  Upregulation of RET induces perineurial invasion of pancreatic adenocarcinoma.

Authors:  M Amit; S Na'ara; L Leider-Trejo; Y Binenbaum; N Kulish; E Fridman; A Shabtai-Orbach; R J Wong; Z Gil
Journal:  Oncogene       Date:  2017-01-16       Impact factor: 9.867

4.  Machine learning for MRI radiomics: a study predicting tumor-infiltrating lymphocytes in patients with pancreatic ductal adenocarcinoma.

Authors:  Yun Bian; Yan Fang Liu; Hui Jiang; Yinghao Meng; Fang Liu; Kai Cao; Hao Zhang; Xu Fang; Jing Li; Jieyu Yu; Xiaochen Feng; Qi Li; Li Wang; Jianping Lu; Chengwei Shao
Journal:  Abdom Radiol (NY)       Date:  2021-06-29

5.  Immunologic and Metabolic Features of Pancreatic Ductal Adenocarcinoma Define Prognostic Subtypes of Disease.

Authors:  Jack Hutcheson; Uthra Balaji; Matthew R Porembka; Megan B Wachsmann; Peter A McCue; Erik S Knudsen; Agnieszka K Witkiewicz
Journal:  Clin Cancer Res       Date:  2016-02-08       Impact factor: 12.531

6.  High immune cell score predicts improved survival in pancreatic cancer.

Authors:  Kyösti Tahkola; Jukka-Pekka Mecklin; Erkki-Ville Wirta; Maarit Ahtiainen; Olli Helminen; Jan Böhm; Ilmo Kellokumpu
Journal:  Virchows Arch       Date:  2018-01-22       Impact factor: 4.064

7.  Evaluation of Early Prognostic Factors in Patients With Pancreatic Ductal Adenocarcinoma Receiving Gemcitabine Together With Nab-paclitaxel.

Authors:  Wataru Izumo; Ryota Higuchi; Toru Furukawa; Takehisa Yazawa; Shuichiro Uemura; Yutaro Matsunaga; Masahiro Shiihara; Masakazu Yamamoto
Journal:  Cancer Diagn Progn       Date:  2021-11-03

8.  Evaluation of an inflammation-based score for identification of appropriate patients for comprehensive genomic profiling.

Authors:  Naomi Hayashi; Ippei Fukada; Akihiro Ohmoto; Masumi Yamazaki; Xiaofei Wang; Mari Hosonaga; Shunji Takahashi
Journal:  Discov Oncol       Date:  2022-10-19

9.  Metabolic tumour burden assessed by ¹⁸F-FDG PET/CT associated with serum CA19-9 predicts pancreatic cancer outcome after resection.

Authors:  Hua-Xiang Xu; Tao Chen; Wen-Quan Wang; Chun-Tao Wu; Chen Liu; Jiang Long; Jin Xu; Ying-Jian Zhang; Run-Hao Chen; Liang Liu; Xian-Jun Yu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-02-13       Impact factor: 9.236

10.  Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug efficacy.

Authors:  Bryan W Miller; Jennifer P Morton; Mark Pinese; Grazia Saturno; Nigel B Jamieson; Ewan McGhee; Paul Timpson; Joshua Leach; Lynn McGarry; Emma Shanks; Peter Bailey; David Chang; Karin Oien; Saadia Karim; Amy Au; Colin Steele; Christopher Ross Carter; Colin McKay; Kurt Anderson; Thomas R Jeffry Evans; Richard Marais; Caroline Springer; Andrew Biankin; Janine T Erler; Owen J Sansom
Journal:  EMBO Mol Med       Date:  2015-08       Impact factor: 12.137

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.